ANKIB1: A Potential Drug Target and Biomarker (G54467)

Target Name: ANKIB1

NCBI ID: G54467

ANKIB1

ANKIB1: A Potential Drug Target and Biomarker

Ankib1, also known asankib1L1, is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Theankib1 gene is located on chromosome 16 and encodes a protein known as ANKIB1, which plays a critical role in the development and progression of these diseases.

Recent studies have suggested that ANKIB1 may be a promising drug target and biomarker for several reasons. First, ANKIB1 has been shown to be highly expressed in various tissues and fluids, including the brain, spinal cord, and peripheral tissues, which suggests that it may be a useful target for drugs that can modulate its expression or activity. Second, several studies have shown that ANKIB1 is involved in the development and progression of several diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. This suggests that it may be a useful biomarker for these diseases and could be used to identify patients who are most likely to respond to a particular treatment.

Furthermore, recent genetic studies have identified several potential variants of the ANKIB1 gene that may be involved in the development and progression of these diseases. For example, one study found that individuals with certain genetic variants, such as those in the ANKIB1 gene, may be at increased risk of developing neurodegenerative disorders. This suggests that ANKIB1 may be an important gene for the development and progression of these disorders, and that targeting ANKIB1 may be a promising strategy for developing new treatments.

In addition to its potential as a drug target and biomarker, ANKIB1 has also been shown to be involved in several important cellular processes that are critical for the development and progression of diseases. For example, ANKIB1 has been shown to be involved in the regulation of cell adhesion, which is important for the development of tissues and organs and is a critical factor in the development of many diseases, including cancer. Additionally, ANKIB1 has been shown to be involved in the regulation of cell signaling pathways, which are important for the development and progression of many diseases, including neurodegenerative disorders.

Given the potential involvement of ANKIB1 in the development and progression of diseases, as well as its high expression in various tissues and its involvement in several important cellular processes, ANKIB1 has the potential to be a valuable drug target and biomarker for a variety of diseases. Further research is needed to fully understand the role of ANKIB1 in the development and progression of diseases and to identify the most effective strategies for targeting it. However, the potential of ANKIB1 as a drug target and biomarker for the prevention and treatment of a wide range of diseases makes it an important area of research for the future.

Protein Name: Ankyrin Repeat And IBR Domain Containing 1

Functions: Might act as an E3 ubiquitin-protein ligase, or as part of E3 complex, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes and then transfers it to substrates

The "ANKIB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKIB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets